Project budget3 801 252 €
ERDF amount2 280 751 €
The common challenge concerned by CoBra project is related to the cancer control plan.
The CoBra project is interested on technological innovation for diagnosis and treatment of localised cancers able to enhance the quality of life for patient and reduce the cancer mortality.
The CoBra project aims to improve the quality of both diagnosis and treatment of localized cancers, by developing innovative technology for biopsy and brachytherapy under MRI control.
- Prototype: to develop a new medical robot prototype for diagnosis and treatment of localized cancers by brachytherapy and biopsy under guidance of MRI. The main localizations are focussed on Prostate and other soft tissues. This prototype will contribute in enhancing the practice of the Brachytherapy in the 2 Seas region. At the end of the project, the concept should be tested on biological subjects, before a technological transfer in the region of the 2 Seas.
- Training: to initiate a training programme for practitioners and physicists on MRI based robotic brachytherapy and biopsy in the 2 Seas region.
- Study: to elaborate a map for targeted cancers dispersion in the region of 2 Seas. This allows estimating the optimal placement of the designed concept in the region of the 2 Seas according to the patient concentration.
- Network: to develop a network of SMEs and Start-up for technological transfer of the new designed concept.
Cross border approach
The fight against cancer is a plan that concerns cross-border countries. The 2 Seas region has complementary competences able to reach the overall objectives of the project. Without this cross-border cooperation, it is not feasible to realize this technological innovation. U-Lille (Fr) will contribute to the development of the robot in collaboration with a SME Demcon (Nl); UT-Delft (Nl) will develop specific needles under IRM control; U-Port. (UK) will work on the time optimization of the treatment plan and the cancer mapping in south of UK. COL (Fr) and NHS (UK) are referenced hospital in the 2 Seas region for the Brachytherapy practice, while Oncovet (Fr) will be a platform for principle proof of the concept for treatment of animal cancers. SATT-Nord (Fr) is a company specialized in the intellectual property of the technological innovation. Finally Eurasanté (Fr) will work on the cancer mapping in the continent and links to SMEs in the exploitation of the results of the project.
During 2020, the CoBra project progressed very well in terms of achieving the goals of developing and integrating the first working prototype of the MR-robot for the biopsy and brachytherapy, with respect to the initial work plan. Thanks to the video conferencing on regular basis (biweekly Technical Meetings among consortium and parter-to-partner weekly meetings) and to the eagerness of the consortium members to complete the tasks according to planning, it has been possible to overcome the pandemic-related limitations and built the first robot prototype that has been assembled, tested successfully with the bio-inspired phantom (first prototype) in the MRI environment.
Compared to the 2019, where the different parts of the integrated solution have been in early development stages, during 2020 the project has been able to attain such objectives as:
- The advanced version of MR- compatible steerable needle module for brachytherapy developed by PP3 in collaboration with LP1 (in the form of regular technical meetings to frame the integration of the module into the robot).
- The MR-compatible biopsy module with the storage system developed and accomplished by PP6 in collaboration with LP1 (in the form of regular technical meetings to frame the integration of the module into the robot).
- MR-compatible seed loader has been developed by the LP1.
The 3D simulation platform has been developed and is currently in progress of integration with the upgraded trajectory planning algorythm and the bio-inspired pahntom for tests and validation of concept at this stage.
The study on socio-economic impacts of the technology innovation has been also conducted and has shown promising results for the CoBra robotic solution to enhance coherence in the diagnosis and treatment of prostate cancers.
The joint intellectual property strategy has been elaborated and companies for technology transfer have been in contact with the project.
CoBra has been involved also in dissemination events like MedFIT 2020 and various workshops notwithstanding the limitations caused by sanitary crisis.
Overall progress of the project has been also presented during the virtual Annual Contact with JS of Interreg 2 Seas in October 2020 which represented positive results and progress achieved thanks to the active and efficient collaboration within the consortium.